| Year |
Citation |
Score |
| 2021 |
Schreck KC, Morin A, Zhao G, Allen AN, Flannery P, Glantz M, Green AL, Jones C, Jones KL, Kilburn LB, Nazemi KJ, Samuel D, Sanford B, Solomon DA, Wang J, ... ... Nicolaides T, et al. Deconvoluting mechanisms of acquired resistance to RAF inhibitors in BRAF V600E mutant human glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34433654 DOI: 10.1158/1078-0432.CCR-21-2660 |
0.302 |
|
| 2020 |
Nicolaides TP, Hashizume R. LSD1 inhibition in pHGG: the key to unleashing immunotherapy? Neuro-Oncology. 22: 1237-1238. PMID 32678903 DOI: 10.1093/Neuonc/Noaa171 |
0.36 |
|
| 2020 |
Miklja Z, Yadav VN, Cartaxo RT, Siada R, Thomas CC, Cummings JR, Mullan B, Stallard S, Paul A, Bruzek AK, Wierzbicki K, Yang T, Garcia T, Wolfe I, Leonard M, ... ... Nicolaides T, et al. Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma. The Journal of Clinical Investigation. PMID 32603316 DOI: 10.1172/Jci133310 |
0.379 |
|
| 2020 |
Tang K, Kurland D, Vasudevaraja V, Serrano J, Delorenzo M, Radmanesh A, Thomas C, Spino M, Gardner S, Allen JC, Nicolaides T, Osorio DS, Finlay JL, Boué DR, Snuderl M. Exploring DNA Methylation for Prognosis and Analyzing the Tumor Microenvironment in Pleomorphic Xanthoastrocytoma. Journal of Neuropathology and Experimental Neurology. PMID 32594172 DOI: 10.1093/Jnen/Nlaa051 |
0.339 |
|
| 2020 |
Nicolaides T, Nazemi KJ, Crawford J, Kilburn L, Minturn J, Gajjar A, Gauvain K, Leary S, Dhall G, Aboian M, Robinson G, Long-Boyle J, Wang H, Molinaro AM, Mueller S, et al. Phase I study of vemurafenib in children with recurrent or progressive BRAF mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget. 11: 1942-1952. PMID 32523649 DOI: 10.18632/Oncotarget.27600 |
0.386 |
|
| 2020 |
Wang H, Long-Boyle J, Winger BA, Nicolaides T, Mueller S, Prados M, Ivaturi V. Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas. Journal of Clinical Pharmacology. PMID 32476174 DOI: 10.1002/Jcph.1617 |
0.337 |
|
| 2020 |
Muldoon D, Zhao G, Batt C, Singh M, Nicolaides T. MODL-17. SHP2 INHIBITORS SHOW ACTIVITY AGAINST NF1-DEFICIENT GLIOMAS AND ENHANCE MAPK PATHWAY INHIBITION IN BRAF-V600E MUTANT GLIOMAS Neuro-Oncology. 22: iii414-iii414. DOI: 10.1093/neuonc/noaa222.591 |
0.353 |
|
| 2020 |
O’Connor M, Lucas M, Romashko D, Rasmussen S, Fiorenza R, Lin T, Waters N, Trainor G, Flohr A, Ottaviani G, Roberts C, Buck E, Nicolaides T, Raleigh D, Ozawa T, et al. EXTH-59. POTENT, SELECTIVE, AND BRAIN PENETRANT INHIBITORS OF EXTRACELLULAR DOMAIN EGFR ONCOGENIC MUTANTS EXPRESSED IN GBM DEMONSTRATE EFFICACY IN AN INTRACRANIAL PATIENT DERIVED XENOGRAFT MODEL Neuro-Oncology. 22: ii100-ii100. DOI: 10.1093/neuonc/noaa215.413 |
0.388 |
|
| 2020 |
Schreck K, Morin A, Zhao G, Sanford B, Green A, Jones K, Banerjee A, Nazemi K, Samuel D, Kilburn L, Solomon D, Pratilas C, Nicolaides T, Levy JM. DDRE-13. DECONVOLUTING MECHANISMS OF RESISTANCE TO BRAF INHIBITORS IN BRAF V600E HUMAN GLIOMA Neuro-Oncology. 22: ii64-ii64. DOI: 10.1093/neuonc/noaa215.258 |
0.354 |
|
| 2019 |
Lavergne V, Sabnis A, Tupule A, Davidson PR, Kline C, Matthay K, Nicolaides T, Goldsby R, Braunstein S, Fogh SE, Sneed PK, Menzel P, Nakamura A, DuBois SG, Haas-Kogan DA, et al. Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy. Journal of Pediatric Hematology/Oncology. PMID 31815884 DOI: 10.1097/Mph.0000000000001668 |
0.333 |
|
| 2019 |
Sabelström H, Petri R, Shchors K, Jandial R, Schmidt C, Sacheva R, Masic S, Yuan E, Fenster T, Martinez M, Saxena S, Nicolaides TP, Ilkhanizadeh S, Berger MS, Snyder EY, et al. Driving Neuronal Differentiation through Reversal of an ERK1/2-miR-124-SOX9 Axis Abrogates Glioblastoma Aggressiveness. Cell Reports. 28: 2064-2079.e11. PMID 31433983 DOI: 10.1016/J.Celrep.2019.07.071 |
0.742 |
|
| 2019 |
McKinney A, Lindberg OR, Engler JR, Chen KY, Kumar A, Gong H, Lu KV, Simonds EF, Cloughesy TF, Liau LM, Prados M, Bollen AW, Berger MS, Shieh JTC, James CD, ... Nicolaides TP, et al. Mechanisms of resistance to EGFR inhibition reveal metabolic vulnerabilities in human GBM. Molecular Cancer Therapeutics. PMID 31270152 DOI: 10.1158/1535-7163.Mct-18-1330 |
0.764 |
|
| 2019 |
Miklja Z, Pasternak A, Stallard S, Nicolaides T, Kline-Nunnally C, Cole B, Beroukhim R, Bandopadhayay P, Chi S, Ramkissoon SH, Mullan B, Bruzek AK, Gauthier A, Garcia T, Atchison C, et al. Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro-Oncology. PMID 30805642 DOI: 10.1093/Neuonc/Noz022 |
0.373 |
|
| 2019 |
O'Connor M, Nicolaides T, Zhang J, Flohr A, Iacone R, Mayweg AV, Epstein DM, Buck E. Abstract LB-111: Epidermal growth factor receptor oncogenes expressed in glioblastoma are activated as covalent dimers and exhibit unique pharmacology Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-111 |
0.428 |
|
| 2019 |
Shen W, Bacha J, Brown D, Kanekal S, Sankar N, Wang Z, Pedersen H, Butowski N, Nicolaides T, Sarkaria J, James CD, Giles F. THER-01. PRECLINICAL DEVELOPMENT OF EO1001, A NOVEL IRREVERSIBLE BRAIN PENETRATING PAN-ErbB INHIBITOR Neuro-Oncology Advances. 1: i10-i11. DOI: 10.1093/NOAJNL/VDZ014.044 |
0.347 |
|
| 2019 |
Nicolaides T, Margol A, Gajjar A, Goldman S, Gauvain K, Kilburn L, Nazemi K, Minturn J, Leary S, Whipple N, Gururangan S, Crawford J, Long-Boyle J, Wang H, Ivaturi V, et al. Ther-26. Pharmacokinetic And Updated Outcome Data From Pnoc-002: A Safety Study Of Vemurafenib, An Oral Inhibitor Of Brafv600E, In Children With Recurrent/Refractory Brafv600E Mutant Brain Tumors Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz036.231 |
0.37 |
|
| 2019 |
Zhao G, Muldoon D, Mo X, Tang C, Fu H, Gustafson WC, Weiss WA, Nicolaides T. Ther-17. Braf-V600E Degradation As A Therapeutic Strategy In Braf-V600E Mutant Gliomas Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz036.224 |
0.725 |
|
| 2019 |
Nobre L, Zapotocky M, Ryall S, Stucklin AG, Bennett J, Baroni L, Sumerauer D, Zamecnik J, Krskova L, Misove A, Pavelka Z, Sterba J, Cruz O, La Madrid AM, Solano P, ... ... Nicolaides T, et al. LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE Neuro-Oncology. 21: ii102-ii102. DOI: 10.1093/Neuonc/Noz036.159 |
0.392 |
|
| 2018 |
Wadhwa EL, Franc BL, Aboian M, Kim JY, Pampaloni M, Nicolaides T. Delayed Fluorodeoxyglucose Positron Emission Tomography Imaging in the Differentiation of Tumor Recurrence and Radiation Necrosis in Pediatric Central Nervous System Tumors: Case Report and Review of the Literature. Cureus. 10: e3364. PMID 30510874 DOI: 10.7759/Cureus.3364 |
0.307 |
|
| 2018 |
Spino M, Kurz SC, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara CM, Frenster JD, Tateishi K, Wakimoto H, Jain R, ... ... Nicolaides T, et al. Cell surface Notch ligand DLL3 is a therapeutic target in isocitrate dehydrogenase mutant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30397180 DOI: 10.1158/1078-0432.Ccr-18-2312 |
0.361 |
|
| 2018 |
Kline C, Liu SJ, Duriseti S, Banerjee A, Nicolaides T, Raber S, Gupta N, Haas-Kogan D, Braunstein S, Mueller S. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. Journal of Neuro-Oncology. PMID 30206764 DOI: 10.1007/S11060-018-2991-5 |
0.302 |
|
| 2018 |
Phillips JJ, Gong H, Chen K, Joseph NM, van Ziffle J, Bastian BC, Grenert JP, Kline CN, Mueller S, Banerjee A, Nicolaides T, Gupta N, Berger MS, Lee HS, Pekmezci M, et al. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Brain Pathology (Zurich, Switzerland). PMID 30051528 DOI: 10.1111/Bpa.12639 |
0.394 |
|
| 2018 |
Grossauer S, Koeck K, Chouchane M, Phillips JJ, Petritsch CK, Nicolaides T. Abstract 143: MAPK pathway blockade effects on glioma stem cells and immunotherapy in BRAFV600E mutant gliomas Cancer Research. 78: 143-143. DOI: 10.1158/1538-7445.Am2018-143 |
0.461 |
|
| 2018 |
Nicolaides TP, Ozawa T, Yao TW, Prados M, Fischer W, Jandeleit B, Koller K. Abstract B125: A novel BBB-permeable chemotherapeutic agent for the treatment of CNS tumors Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B125 |
0.38 |
|
| 2018 |
Zapotocky M, Ryall S, Fukuoka K, Stucklin AG, Bennett J, Sumerauer D, Pavelka Z, Cruz O, Solano P, Garre ML, Hauser P, Frappaz D, Hansford J, Amayiri N, Morse H, ... ... Nicolaides T, et al. Lgg-59. Remarkable Objective Response And Favorable Survival For Braf-V600E Childhood Low-Grade Gliomas To Braf Inhibitors Compared Conventional Chemotherapy Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy059.399 |
0.371 |
|
| 2017 |
Lassaletta A, Zapotocky M, Mistry M, Ramaswamy V, Honnorat M, Krishnatry R, Guerreiro Stucklin A, Zhukova N, Arnoldo A, Ryall S, Ling C, McKeown T, Loukides J, Cruz O, de Torres C, ... ... Nicolaides T, et al. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016718726. PMID 28727518 DOI: 10.1200/Jco.2016.71.8726 |
0.393 |
|
| 2017 |
Fan QW, Nicolaides TP, Weiss WA. Inhibiting 4EBP1 in glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28696243 DOI: 10.1158/1078-0432.Ccr-17-0042 |
0.658 |
|
| 2017 |
Kline CN, Joseph NM, Grenert JP, van Ziffle J, Talevich E, Onodera C, Aboian M, Cha S, Raleigh DR, Braunstein S, Torkildson J, Samuel D, Bloomer M, Campomanes AGA, Banerjee A, ... ... Nicolaides T, et al. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro-Oncology. 19: 699-709. PMID 28453743 DOI: 10.1093/Neuonc/Now254 |
0.354 |
|
| 2017 |
Ulasov IV, Foster H, Butters M, Yoon JG, Ozawa T, Nicolaides T, Figueroa X, Hothi P, Prados M, Butters J, Cobbs C. Precision knockdown of EGFR gene expression using radio frequency electromagnetic energy. Journal of Neuro-Oncology. PMID 28434113 DOI: 10.1007/S11060-017-2440-X |
0.374 |
|
| 2017 |
Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro-Oncology. PMID 28339824 DOI: 10.1093/Neuonc/Now282 |
0.428 |
|
| 2017 |
Fan Q, Aksoy O, Wong RA, Ilkhanizadeh S, Novotny CJ, Gustafson WC, Truong AY, Cayanan G, Simonds EF, Haas-Kogan D, Phillips JJ, Nicolaides T, Okaniwa M, Shokat KM, Weiss WA. A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. Cancer Cell. 31: 424-435. PMID 28292440 DOI: 10.1016/J.Ccell.2017.01.014 |
0.743 |
|
| 2017 |
Sabelstrom H, Petri R, Shchors K, Jandial R, Sacheva R, Masic S, Yuan E, Fenster T, Nicolaides T, IIkhanizadeh S, Berger MS, Snyder E, Weiss W, Jakobsson J, Persson A. STEM-11. A MAPK-DRIVEN miR-124-SOX9 AXIS IS CRITICAL FOR STEM CELL MAINTENANCE, PROGRESSION, AND THERAPY-RESISTANCE IN GLIOBLASTOMA Neuro-Oncology. 19: vi228-vi228. DOI: 10.1093/Neuonc/Nox168.927 |
0.59 |
|
| 2017 |
Wadhwa E, Zhang J, Powell B, Van C, Gustafson C, Nicolaides T. PDTM-15. PLX51107, A NOVEL BROMODOMAIN INHIBITOR, WORKS SYNERGISTICALLY WITH AURORA-A KINASE INHIBITOR MLN8327 IN TREATING MYC-AMPLIFIED MEDULLOBLASTOMA Neuro-Oncology. 19: vi192-vi192. DOI: 10.1093/neuonc/nox168.779 |
0.337 |
|
| 2017 |
Nicolaides T, Nazemi K, Crawford J, Kilburn L, Minturn J, Gajjar A, Gauvain K, Leary S, Dhall G, Aboian M, Robinson G, Molinaro A, Mueller S, Prados M. PDCT-19. A SAFETY STUDY OF VEMURAFENIB, AN ORAL INHIBITOR OF BRAFV600E, IN CHILDREN WITH RECURRENT/REFRACTORY BRAFV600E MUTANT BRAIN TUMORS: PNOC-002 Neuro-Oncology. 19: vi188-vi188. DOI: 10.1093/Neuonc/Nox168.761 |
0.34 |
|
| 2017 |
Zhai B, Steino A, Bacha J, Brown D, Daugaard M, Nicolaides T. Hgg-02. Dianhydrogalactitol (Val-083) Overcomes Mgmt- And P53-Mediated Chemo-Resistance And Displays Synergy With Topoisomerase Inhibitors Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox083.091 |
0.349 |
|
| 2016 |
Torchia J, Golbourn B, Feng S, Ho KC, Sin-Chan P, Vasiljevic A, Norman JD, Guilhamon P, Garzia L, Agamez NR, Lu M, Chan TS, Picard D, de Antonellis P, Khuong-Quang DA, ... ... Nicolaides T, et al. Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell. 30: 891-908. PMID 27960086 DOI: 10.1016/J.Ccell.2016.11.003 |
0.388 |
|
| 2016 |
Zhang J, Yao TW, Hashizume R, Hariono S, Barkovich KJ, Fan QW, Prados M, James CD, Weiss WA, Nicolaides T. Combined BRAF(V600E) and MEK blockade for BRAF(V600E)-mutant gliomas. Journal of Neuro-Oncology. PMID 27848137 DOI: 10.1007/S11060-016-2333-4 |
0.662 |
|
| 2016 |
Grossauer S, Koeck K, Murphy NE, Meyers ID, Daynac M, Truffaux N, Truong AY, Nicolaides TP, McMahon M, Berger MS, Phillips JJ, James CD, Petritsch CK. Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Oncotarget. PMID 27713119 DOI: 10.18632/Oncotarget.12419 |
0.547 |
|
| 2016 |
Packer RJ, Pfister S, Bouffet E, Avery R, Bandopadhayay P, Bornhorst M, Bowers DC, Ellison D, Fangusaro J, Foreman N, Fouladi M, Gajjar A, Haas-Kogan D, Hawkins C, Ho CY, ... ... Nicolaides T, et al. Pediatric low-grade gliomas: implications of the biologic era. Neuro-Oncology. PMID 27683733 DOI: 10.1093/Neuonc/Now209 |
0.301 |
|
| 2016 |
Phillips JJ, Gong H, Chen K, Joseph NM, van Ziffle J, Jin LW, Bastian BC, Bollen AW, Perry A, Nicolaides T, Solomon DA, Shieh JT. Activating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p.V600E mutation. Acta Neuropathologica. PMID 27624885 DOI: 10.1007/S00401-016-1616-3 |
0.32 |
|
| 2016 |
Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T. Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas. Oncotarget. PMID 27611946 DOI: 10.18632/Oncotarget.11882 |
0.661 |
|
| 2016 |
Wadhwa E, Nicolaides T. Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors. Cureus. 8. PMID 27382528 DOI: 10.7759/Cureus.620 |
0.421 |
|
| 2016 |
Jones C, Karajannis MA, Jones DT, Kieran MW, Monje M, Baker SJ, Becher OJ, Cho YJ, Gupta N, Hawkins C, Hargrave D, Haas-Kogan DA, Jabado N, Li XN, Mueller S, ... Nicolaides T, et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro-Oncology. PMID 27282398 DOI: 10.1093/Neuonc/Now101 |
0.729 |
|
| 2016 |
Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA. Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. Journal of Neuro-Oncology. PMID 26782702 DOI: 10.1007/S11060-015-2024-6 |
0.568 |
|
| 2016 |
Hou Y, Kohanbash G, Okada K, Shrivastav S, Smith-Cohn M, Nicolaides T, Mueller S, Carcaboso AM, Pollack IF, Okada H. Abstract A117: Novel and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3 K27M mutation Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A117 |
0.305 |
|
| 2016 |
Sabelstrom H, Jandial R, Shchors K, Masic S, Yuan E, Fenster T, Saxena S, Ho A, Nicolaides TP, Wong R, Yakovenko S, Berger MH, Snyder EY, Jakobsson J, Weiss WA, et al. Abstract 1916: Targeting a MAPK-miR-124-Sox9 axis radiosensitizes human glioblastoma cells Cancer Research. 76: 1916-1916. DOI: 10.1158/1538-7445.Am2016-1916 |
0.624 |
|
| 2016 |
Kline C, Solomon D, Perry A, Bastian B, Joseph N, Phillips J, Tihan T, Yeh I, Van Ziffle J, Grenert J, Bollen A, Mueller S, Banerjee A, Gupta N, Raffel C, ... ... Nicolaides T, et al. TB-02UPFRONT, REAL-TIME TUMOR AND GERMLINE SEQUENCING OF PEDIATRIC BRAIN TUMOR PATIENTS: THE UCSF EXPERIENCE Neuro-Oncology. 18: iii169.2-iii169. DOI: 10.1093/Neuonc/Now084.02 |
0.308 |
|
| 2016 |
Lassaletta A, Mistry M, Arnaldo A, Ryall S, Guerreiro-Stucklin A, Krishnatry R, Ling C, Honnorat M, Zhukova N, Zapotocky M, McKeown T, Ramaswamy V, Bartels U, Huang A, Jabado N, ... ... Nicolaides T, et al. Lg-46Inferior Outcome And Poor Response To Conventional Therapies In Pediatric Low-Grade Gliomas Harboring The Braf V600E Mutation. Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now075.46 |
0.344 |
|
| 2016 |
Mueller S, Liang W, Gupta N, Kuhn J, Kilburn L, Crawford J, Banerjee A, Nazemi K, Packer R, Nazarian J, Petritsch C, Truffaux N, Roos A, Nicolaides T, Waanders A, et al. Hg-115Precision Medicine Approach For Children With Diffuse Intrinsic Pontine Glioma Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now073.111 |
0.353 |
|
| 2015 |
Lerner RG, Grossauer S, Kadkhodaei B, Meyers I, Sidorov M, Koeck K, Hashizume R, Ozawa T, Phillips JJ, Berger MS, Nicolaides T, James CD, Petritsch CK. Targeting a Plk1-controlled polarity checkpoint in therapy-resistant glioblastoma-propagating cells. Cancer Research. PMID 26573800 DOI: 10.1158/0008-5472.Can-14-3689 |
0.395 |
|
| 2015 |
Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Oncotarget. PMID 26023796 DOI: 10.18632/Oncotarget.4014 |
0.676 |
|
| 2015 |
Yao T, Nicolaides T, Sarkaria J, James CD. NT-113, A Novel, High CNS Penetrance pan-ERBB Inhibitor for Glioma Therapy Therapeutic Targets For Neurological Diseases. 2. DOI: 10.14800/Ttnd.585 |
0.539 |
|
| 2015 |
Hou Y, Kohanbash G, Okada K, Shrivastav S, Smith-Cohn M, Nicolaides T, Mueller S, Carcaboso A, Pollack I, Okada H. Novel and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3 K27M mutation Journal For Immunotherapy of Cancer. 3: 445. DOI: 10.1186/2051-1426-3-S2-P445 |
0.351 |
|
| 2015 |
Zhang J, Yao T, Truong A, Nicolaides T. PTPS-30COMPARISON OF MAPK PATHWAY TARGETS AS POTENTIAL THERAPIES FOR MAPK-ACTIVATED GLIOMAS Neuro-Oncology. 17: v185.4-v185. DOI: 10.1093/Neuonc/Nov228.30 |
0.499 |
|
| 2015 |
Serwer L, Le Moan N, Regan M, Blecha J, Davis A, Tanaka K, Keating T, Romero J, Leung P, Davis T, Bedard C, Ng S, Yan F, Santos R, Ozawa T, ... ... Nicolaides T, et al. NIMG-45REAL-TIME PET IMAGING DEMONSTRATES TUMOR ACCUMULATION AND OXYGENATION BY OMX-4.80P, AN OXYGEN CARRIER ENGINEERED FOR THE TREATMENT OF GLIOBLASTOMA Neuro-Oncology. 17: v164.1-v164. DOI: 10.1093/Neuonc/Nov225.45 |
0.312 |
|
| 2015 |
Fan Q, Wong R, Novotny C, Okaniwa M, Nicolaides T, Shokat K, Weiss W. ATPS-94THIRD GENERATION mTOR INHIBITORS IN GLIOBLASTOMA Neuro-Oncology. 17: v39.2-v39. DOI: 10.1093/Neuonc/Nov204.94 |
0.637 |
|
| 2015 |
Sabelstrom H, Jandial R, Shchors K, Masic S, Ho A, Vandenberg S, Nicolaides TP, Nguyen K, Yakovenko S, Prados MD, James CD, Berger MS, Evan GI, Snyder EY, Weiss WA, et al. HG-13 * SOX9 AS A DOWN-STREAM TARGET IN RAS/MEK-DRIVEN PEDIATRIC GLIOMA Neuro-Oncology. 17: iii13-iii13. DOI: 10.1093/Neuonc/Nov061.50 |
0.611 |
|
| 2015 |
Yao T, Zhang J, Prados M, Weiss W, James D, Nicolaides T. SG-01 * FEEDBACK ACTIVATION OF EGFR VIA PTPN9 LEADS TO GLIOMA ESCAPE FROM BRAFV600E TARGETED THERAPY Neuro-Oncology. 17: iii34-iii35. DOI: 10.1093/Neuonc/Nov061.139 |
0.674 |
|
| 2014 |
Yoshida Y, Ozawa T, Yao TW, Shen W, Brown D, Parsa AT, Raizer JJ, Cheng SY, Stegh AH, Mazar AP, Giles FJ, Sarkaria JN, Butowski N, Nicolaides T, James CD. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification. Molecular Cancer Therapeutics. 13: 2919-29. PMID 25313012 DOI: 10.1158/1535-7163.Mct-14-0306 |
0.486 |
|
| 2014 |
Banerjee A, Jakacki R, Onar-Thomas A, Wu S, Nicolaides T, Turner D, Richardson S, Young-Poussaint T, Phillips JJ, Prados M, Packer R, Qaddoumi IA, Gururangan S, Goldman S, Pollack I, et al. A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report. Journal of Clinical Oncology. 32: 10065-10065. DOI: 10.1200/Jco.2014.32.15_Suppl.10065 |
0.34 |
|
| 2014 |
Yao T(, Yoshida Y, Zhang J, Ozawa T, James D, Nicolaides T. Abstract LB-208: Targeting resistance pathways in BRAF-mutant pediatric gliomas Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-208 |
0.503 |
|
| 2014 |
Nicolaides T, Yao TW, Yoshida Y, Zhang J, Ozawa T, James D. Targeting Resistance Pathways In Braf-Mutant Pediatric Gliomas Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou208.18 |
0.529 |
|
| 2013 |
Cage TA, Samagh SP, Mueller S, Nicolaides T, Haas-Kogan D, Prados M, Banerjee A, Auguste KI, Gupta N. Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children Childs Nervous System. 29: 1313-1319. PMID 23666401 DOI: 10.1007/S00381-013-2101-0 |
0.312 |
|
| 2013 |
Aaberg-Jessen C, Fogh L, Halle B, Jensen V, Brunner N, Kristensen BW, Abe T, Momii Y, Watanabe J, Morisaki I, Natsume A, Wakabayashi T, Fujiki M, Aldaz B, Fabius AWM, ... ... Nicolaides TP, et al. EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY Neuro-Oncology. 15: iii37-iii61. DOI: 10.1093/Neuonc/Not176 |
0.482 |
|
| 2012 |
Hashizume R, Smirnov I, Liu S, Phillips JJ, Hyer J, McKnight TR, Wendland M, Prados M, Banerjee A, Nicolaides T, Mueller S, James CD, Gupta N. Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment. Journal of Neuro-Oncology. 110: 305-13. PMID 22983601 DOI: 10.1007/S11060-012-0973-6 |
0.393 |
|
| 2012 |
Barkovich KJ, Hariono S, Garske AL, Zhang J, Blair JA, Fan QW, Shokat KM, Nicolaides T, Weiss WA. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discovery. 2: 450-7. PMID 22588882 DOI: 10.1158/2159-8290.Cd-11-0287 |
0.608 |
|
| 2012 |
Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, Aoki Y, Nicolaides T, Perry A, Waldman T, McMahon M, Weiss WA, Petritsch C, James CD, Rowitch DH. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proceedings of the National Academy of Sciences of the United States of America. 109: 8710-5. PMID 22586120 DOI: 10.1073/Pnas.1117255109 |
0.616 |
|
| 2012 |
See WL, Tan IL, Mukherjee J, Nicolaides T, Pieper RO. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. Cancer Research. 72: 3350-9. PMID 22573716 DOI: 10.1158/0008-5472.Can-12-0334 |
0.439 |
|
| 2012 |
Dasgupta T, Yang X, Hashizume R, Olow A, Kolkowitz I, Weiss W, Mueller S, Nicolaides T, James C, Haas-Kogan D. Survival Advantage With Radiation Combined With a Selective BRAFV600E Inhibitor in an Orthotopic, Intracranial Model of BRAFV600E-mutated High-grade Gliomas International Journal of Radiation Oncology*Biology*Physics. 84: S125. DOI: 10.1016/J.Ijrobp.2012.07.125 |
0.504 |
|
| 2011 |
Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, Baker SJ, Paugh BS, Jones C, Forshew T, Hindley GF, Hodgson JG, Kim JS, Rowitch DH, Weiss WA, et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7595-604. PMID 22038996 DOI: 10.1158/1078-0432.Ccr-11-1456 |
0.628 |
|
| 2011 |
West BL, Tsai J, Nicolaides T, Wong B, Nguyen H, Marimuthu A, Ibrahim P, Hirth P, Bollag G. Abstract 552: Targeting brain tumors with PLX3397, an inhibitor of the CSF-1 receptor kinase Cancer Research. 71: 552-552. DOI: 10.1158/1538-7445.Am2011-552 |
0.374 |
|
| 2011 |
Barkovich KJ, Nicolaides T, Hariono S, Garske A, Fan QW, Shokat K, Weiss WA. Abstract 2314: Erlotinib response in lung- and glioma-derived EGFR alleles: Correlating kinase site occupancy with efficacy Cancer Research. 71: 2314-2314. DOI: 10.1158/1538-7445.Am2011-2314 |
0.599 |
|
| 2011 |
Pavel H, Ajeawung N, Faure R, Poirier D, Kamnasaran D, Ajeawung N, Joshi H, Kamnasaran D, Poirier D, Ajeawung N, Kamnasaran D, Lun X, Zemp F, Sun B, Stechishin O, ... ... Nicolaides T, ... ... Nicolaides T, ... ... Nicolaides T, et al. PRECLINICAL EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY Neuro-Oncology. 13: iii107-iii120. DOI: 10.1093/Neuonc/Nor158 |
0.492 |
|
| 2010 |
Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA, Debnath J, Shokat KM, Weiss WA. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Science Signaling. 3: ra81. PMID 21062993 DOI: 10.1126/Scisignal.2001017 |
0.781 |
|
| 2010 |
Yoon DJ, Kwan BH, Chao FC, Nicolaides TP, Phillips JJ, Lam GY, Mason AB, Weiss WA, Kamei DT. Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery. Cancer Research. 70: 4520-7. PMID 20460527 DOI: 10.1158/0008-5472.Can-09-4311 |
0.553 |
|
| 2010 |
Nicolaides T, Tihan T, Horn B, Biegel J, Prados M, Banerjee A. High-dose chemotherapy and autologous stem cell rescue for atypical teratoid/rhabdoid tumor of the central nervous system. Journal of Neuro-Oncology. 98: 117-23. PMID 19936623 DOI: 10.1007/S11060-009-0071-6 |
0.323 |
|
| 2010 |
Nicolaides TP, Barkovich K, Hariono S, Garske A, Fan QW, Shokat K, Weiss WA. Abstract 1973: Targeting activated alleles of EGFR derived from glioma and lung cancer: Correlating kinase active-site occupancy with efficacy Cancer Research. 70: 1973-1973. DOI: 10.1158/1538-7445.Am10-1973 |
0.618 |
|
| 2007 |
Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Research. 67: 7960-5. PMID 17804702 DOI: 10.1158/0008-5472.Can-07-2154 |
0.787 |
|
| 2004 |
Broniscer A, Nicolaides TP, Dunkel IJ, Gardner SL, Johnson J, Allen JC, Sposto R, Finlay JL. High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumors. Pediatric Blood & Cancer. 42: 261-7. PMID 14752864 DOI: 10.1002/Pbc.10369 |
0.301 |
|
| Show low-probability matches. |